Real-world trials to answer real-world questions

PharmacoEconomics

Volumn 23, Issue 8, 2005, Pages 747-754

  Freemantle, Nick ^a   Blonde, Lawrence ^b   Bolinder, Bjorn ^c   Gerber, Robert A ^d   Hobbs, F D Richard ^a   Martinez, Luc ^e   Ross, Stuart ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c SANOFI   (France)

^d PFIZER INC   (United States)

^e Societe Francaise de Medecine Generale   (France)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; STATISTICAL ANALYSIS;

CLINICAL TRIALS; DRUG THERAPY; HEALTH POLICY; HUMANS; REIMBURSEMENT MECHANISMS; SOCIAL PROBLEMS;

EID: 26444508546     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523080-00001     Document Type: Review

References (19)

1. Freemantle N. Does the UK need a fourth hurdle for pharmaceutical reimbursement to encourage the more cost effective prescribing of pharmaceuticals? Health Policy 1999; 46: 255-65
2. The National Institute for Clinical Excellence (NICE) [online]. Available from URL: http://www.nice.org.uk [Accessed 2004 Nov 25]
3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline, statistical principles for clinical trials. Stat Med 1999; 18: 1905-42
4. Freemantle N. Interpreting the results of secondary endpoints and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ 2001; 322: 989-91
5. Hajalmarson Å, Goldstein S, Fagerberg B, et al. Effects of controlled release metoprolol on total mortality, hospitalisations and well being in patients with heart failure. The MEtoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295-302
6. Freemantle N. Cost effectiveness of non steroidal anti inflammatory drugs: what makes an NSAID good value for money? Rheumatology 2000; 39: 232-4
7. Freemantle N, Drummond MF. Should clinical trials with con-current economic analyses be blinded? JAMA 1997; 277: 63-4
8. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7-22
9. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33
10. Klonoff DC. Inhaled insulin. Diabetes Technol Ther 1999; 1: 307-13
11. Skyler JS, Cefalu WT, Kourides I, et al. Efficacy of inhaled insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-5
12. Cefalu WT, Skyler JS, Kourides I, et al. Inhaled human insulin treatment of patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-7
13. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72
14. Quattrin T, Bélanger A, Bohannon NJV, et al., for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004; 27: 2622-7
15. Hollander PA, Blonde L. Rowe R, et al., for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004; 27: 2356-62
16. Cefalu WT, for the Exubera® Phase III Study Group. Mealtime rapid-acting inhaled insulin (Exubera®) improves glycaemic control in patients with type 2 diabetes failing combination oral agents: a 3-month, randomised, comparative trial [abstract]. Diabetologia 2002; 45: A260
17. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28: 427-8
18. Blonde L, Freemantle N, Ross SA, et al. The availability of inhaled insulin leds to improved health outcomes in patients with uncontrolled type 2 diabetes [abstract]. Diabetologia 2004; 47 Suppl. 1: A310
19. Gold MR, Siegel JE, Russel RB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 31